Emergent BioSolutions Inc. (EBS) Income statement

Market cap

$446.71M

P/E ratio

	2011/12	2012/12	2013/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Revenue	273	282	313	523	489	561	782	1,106	1,555	1,793	1,121	1,049	1,044
Revenue growth (%)	-			-
Cost of revenue	42	46	62	124	131	196	322	434	524	-	694	705	-
Research & development	125	120	120	154	108	97	143	226	235	234	193	111	71
Selling, general & administrative	74	76	88	148	144	143	203	274	303	348	340	368	308
Operating margin (%)
Operating expenses	-	-	-	-	-	-	693	992	-	-	-	-	-
Operating income	32	30	43	96	106	124	90	114	434	353	-173	-726	-109
Income before tax	32	32	43	90	99	119	82	77	407	314	-222	-731	-143
Pretax margin (%)	11.7	11.4	13.9	17.2	20.3	21.2	10.4	7	26.2	17.5	-19.8	-69.7	-13.7
Provision for income taxes	16	14	13	27	37	36	19	23	102	84	2	29	48
Effective tax rate (%)
Net income	23	24	31	63	52	83	63	55	305	231	-224	-760	-191
Net income margin (%)
Earnings per share	0.65	0.65	0.86	1.63	1.29	1.98	1.25	1.06	5.79	4.32	-4.47	-14.85	-3.6
Diluted EPS	0.64	0.65	0.85	1.41	1.13	1.71	1.22	1.04	5.67	4.27	-4.47	-14.85	-3.6
EBITDA				-	-	-	-	-	-	-	-
EBITDA margin (%)				-	-	-	-	-	-	-	-